Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
The phase 1b/2 PLANET study tested the combination of lanreotide and pembrolizumab in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Kasi et al compared a novel, artificial intelligence (AI)-based cancer clinical trial search tool with ClinicalTrials.gov to determine which afforded a better user experience.
A cross-sectional survey assessed health-related quality of life in colorectal cancer survivors (≤50 years).
Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.
Continued follow-up showed nivolumab conferred benefit regardless of best overall response.
ATTRACTION-1 investigators report the final findings from the study, derived from a minimum follow-up of 5 years.
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Investigators of the SUMMIT basket trial evaluated the efficacy of neratinib both as a monotherapy and in combination with other agents in patients with fibrolamellar carcinoma (FLC).
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).